Positron emission mammography in the evaluation of interim response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

Soldevilla-Gallardo, Irma; Villaseñor‐Navarro, Yolanda; Medina-Ornelas, Sevastián S.; Villarreal‐Garza, Cynthia; Bargalló-Rocha, Enrique; Caro-Sánchez, Claudia Haydeé Saraí; Gallardo-Alvarado, Lenny; Hernández-Ramírez, Rodrigo; Arela-Quispe, Liz; García-Pérez, Francisco O.

doi:10.1016/j.ctarc.2018.05.001

Cited by 3 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecular imaging is a highly repeatable, safe, and noninvasive imaging technique that has been widely used in the diagnosis, staging, prognosis prediction, and efficacy evaluation of various malignant tumors, including breast cancer, which is an ideal method for identifying breast cancer subtypes. , Compared to other imaging methods, immunoPET is currently the most promising molecular imaging method and combines high specificity, affinity, and antibody sensitivity. It is expected to be widely used to enable clinicians not only to see the location of tumors in vivo but also to visualize the expression, activity, and biological processes of specific molecules. , Previous studies have shown that immunoPET imaging of 89 Zr-labeled trastuzumab can characterize the HER2 status of breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

ImmunoPET of CD146 in Orthotopic and Metastatic Breast Cancer Models

Liu

Fan

et al. 2021

Bioconjugate Chem.

View full text Add to dashboard Cite

The overexpression of CD146 in breast cancer is considered a hallmark of tumor progression and metastasis, particularly in triple negative breast cancer. Aimed at imaging differential CD146 expressions in breast cancer, a noninvasive method for predictive prognosis and diagnosis was investigated using a 64Cu-labeled CD146-specific monoclonal antibody, YY146. CD146 expression was screened in human breast cancer cell lines using Western blotting. Binding ability was evaluated using flow cytometry and immunofluorescent staining. YY146 was conjugated with 1,4,7-triazacyclononane-triacetic acid (NOTA) and radiolabeled with 64Cu following standard procedures. Serial PET or PET/CT imaging was performed in orthotopic and metastatic breast cancer tumor models. Biodistribution was performed after the final time point of imaging. Finally, tissue immunofluorescent staining and hematoxylin and eosin (H&E) staining were performed on tumor tissues. The MDA-MB-435 cell line showed the highest CD146 expression level, whereas MCF-7 had the lowest level at the cellular level. ImmunoPET showed that MDA-MB-435 orthotopic tumors had high and clear radioactive accumulation after the administration of 64Cu-NOTA-YY146. The tumor uptake of 64Cu-NOTA-YY146 in MDA-MB-435 was significantly higher than that in MCF-7 and nonspecific IgG control groups (P < 0.01). Biodistribution verified the PET imaging results. For metastatic models, 64Cu-NOTA-YY146 allowed for the visualization of high radioactivity accumulation in metastatic MDA-MB-435 tumors, which was confirmed by ex vivo biodistribution of lung tissues. H&E staining proved the successful building of metastatic tumor models. Immunofluorescent staining verified the differential expression of CD146 in orthotopic tumors. Therefore, 64Cu-NOTA-YY146 could be used as an immunoPET probe to visualize CD146 in the breast cancer model and is potentially useful for cancer diagnosis, prognosis prediction, and monitoring therapeutic response.

show abstract

Section: Discussionmentioning

confidence: 99%

ImmunoPET of CD146 in Orthotopic and Metastatic Breast Cancer Models

Liu

Fan

et al. 2021

Bioconjugate Chem.

View full text Add to dashboard Cite

show abstract

“…Molecular subtypes of breast cancer were divided into Luminal A, Luminal B HER2‐positive, Luminal B HER2‐negative, HER2‐enriched and Triple negative . The histologic response was estimated on the basis of Miller and Payne grade (MPG), and the MPG was categorized into five grades in line with the number of tumour cells in excision/ mastectomy specimens compared with the pre‐treatment core biopsy as follows :(a) grade 1, no reduction in total number of cancer cells; (b) grade 2, minor (<30%) loss of total number of cancer cells; (c) grade 3, estimated 30%‐90% reduction in total number of cancer cells; (d) grade 4, over (>90%) loss of total number of cancer cells; 5) grade 5, no infiltrating cancer (IC), or ductal carcinoma in situ. Histologic tumour grade was accessed by the Elston‐Ellis modification of Scarff‐Bloom‐Richardson grading system and based on three factors, such as: (a) the amount of gland formation; (b) the nuclear features; and (c) the mitotic activity.…”

Section: Methodsmentioning

confidence: 99%

“…Molecular subtypes of breast cancer were divided into Luminal A, Luminal B HER2-positive, Luminal B HER2-negative, HER2-enriched and Triple negative. 29 The histologic response was estimated on the basis of Miller and Payne grade (MPG), and the MPG was categorized into five grades in line with the number of tumour cells in excision/ mastectomy specimens compared with the pretreatment core biopsy as follows 30 (a) grade I, the total score of tumours was 3-5 points; (b) grade II, the total score of tumours was 6-7 points; (c) grade III, the total score of tumours was 8-9 points. The response rate was defined in the light of the Response Evaluation Criteria In Solid Tumours (RECIST) guidelines and was stratified into four groups: complete response (CR), partial response (PR), stable disease (SD) and progression of disease (PD).…”

Section: Classification Criteria and Response Evaluationmentioning

confidence: 99%

Pre‐treatment systemic immune‐inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy

Chen

Kong

Wang

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

The systemic immune‐inflammation index (SII = N × P/L) based on neutrophil (N), platelet (P) and lymphocyte (L) counts is used to predict the survival of patients with malignant tumours and can fully reflect the balance between host inflammatory and immune status. This study is conducted to explore the potential prognostic significance of SII in patients with breast cancer undergoing neoadjuvant chemotherapy (NACT). A total of 262 patients with breast cancer received NACT were enrolled in this study. According to the receiver operating characteristic curve, the optimal cut‐off value of SII was divided into two groups: low SII group (<602 × 109/L) and high SII group (≥602 × 109/L). The associations between breast cancer and clinicopathological variables by SII were determined by chi‐squared test or Fisher's exact test. The Kaplan‐Meier plots and log‐rank test were used to determine clinical outcomes of disease‐free survival (DFS) and overall survival (OS). The prognostic value of SII was analysed by univariate and multivariate Cox proportional hazards regression models. The toxicity of NACT was accessed by National Cancer Institute Common Toxicity Criteria (NCICTC). According to univariate and multivariate Cox regression survival analyses, the results showed that the value of SII had prognostic significance for DFS and OS. The patients with low SII value had longer DFS and OS than those with high SII value (31.11 vs 40.76 months, HR: 1.075, 95% CI: 0.718‐1.610, P = .006; 44.47 vs 53.68 months, HR: 1.051, 95% CI: 0.707‐1.564, P = .005, respectively). The incidence of DFS and OS in breast cancer patients with low SII value was higher than that in those patients with high SII value in 3‐, 5‐ and 10‐year rates. The common toxicities after NACT were haematological and gastrointestinal reaction, and there were no differences by SII for the assessment of side effects of neoadjuvant chemotherapy. Meanwhile, the results also proved that breast cancer patients with low SII value and high Miller and Payne grade (MPG) survived longer than those breast cancer with high SII value and low MPG grade. In patients without lymph vessel invasion, these breast cancer patients with low SII value had better prognosis and lower recurrence rates than those with high SII value. Pre‐treatment SII with the advantage of reproducible, convenient and non‐invasive was a useful prognostic indicator for breast cancer patients undergoing neoadjuvant chemotherapy and is a promising biomarker for breast cancer on treatment strategy decisions.

show abstract

“…In particular, Soldevilla et al used PEM for interim prediction of the response to NAC in a retrospective study enrolling 108 patients. Though further studies are required to validate these results, SUVmax and lesion to background (LTB) showed strong correlation with pCR [ 66 ].…”

Section: Prediction Of Response To Nacmentioning

confidence: 99%

Assessment and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Imaging Modalities and Future Perspectives

Romeo

Accardo

Perillo

et al. 2021

Cancers

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NAC) is becoming the standard of care for locally advanced breast cancer, aiming to reduce tumor size before surgery. Unfortunately, less than 30% of patients generally achieve a pathological complete response and approximately 5% of patients show disease progression while receiving NAC. Accurate assessment of the response to NAC is crucial for subsequent surgical planning. Furthermore, early prediction of tumor response could avoid patients being overtreated with useless chemotherapy sections, which are not free from side effects and psychological implications. In this review, we first analyze and compare the accuracy of conventional and advanced imaging techniques as well as discuss the application of artificial intelligence tools in the assessment of tumor response after NAC. Thereafter, the role of advanced imaging techniques, such as MRI, nuclear medicine, and new hybrid PET/MRI imaging in the prediction of the response to NAC is described in the second part of the review. Finally, future perspectives in NAC response prediction, represented by AI applications, are discussed.

show abstract

Positron emission mammography in the evaluation of interim response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

Cited by 3 publications

References 30 publications

ImmunoPET of CD146 in Orthotopic and Metastatic Breast Cancer Models

ImmunoPET of CD146 in Orthotopic and Metastatic Breast Cancer Models

Pre‐treatment systemic immune‐inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy

Assessment and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Imaging Modalities and Future Perspectives

Contact Info

Product

Resources

About